| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Filana Therapeutics, Inc.
$0.82
-0.01 (-1.46%)
C 41Pipeline Score Biotech · Pre-Clinical
Market Cap
39.43 M
EPS
-1.61
P/E Ratio
-
Value Trade
532.94 K
-12.21 %
Week
-15.02 %
1 Month
-38.21 %
3 Month
-60.98 %
6 Month
-97.38 %
5 Year
-98.71 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
182.10 K
52 Week Range
1.16 - 4.98
% held by Insiders
2.05 %
% held by Institutions
26.25 %
Enterprise Value
-47.06 M
Total Shares
48.29 M
Short %
13.34 %
Float Shares
45.59 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Filana Therapeutics, Inc.
64Total events
3Upcoming
16Tier-1 (high impact)
2006 – 2026Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
●Other Regulator MilestoneEx-US Regulatory
Subscribe to view catalyst details
TBD
●PublicationsimufilamPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C41
Pipeline Score $0M
Pipeline ValueValuation Signal
6
Drugs Scored—
rNPV / MCap Top 64%
Micro Cap (rank 339 of 938)
Percentile RankFilana Therapeutics, Inc. carries a moderate pipeline score (41/100), with $859M risk-adjusted pipeline value, led by Simufilam in Alzheimer Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simufilam Small molecule | Alzheimer Disease | Phase 3 | NCT04079803 | 44% | $283M | - | 1,088 | - | - | — | - | - |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FLNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FLNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
FLNAFilana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Filana Therapeutics reported its Q2 2026 financial results, highlighting a net loss of $8.6 million. The company is working to lift a clinical hold on its trial for TSC-related epilepsy and is actively engaging with the TSC community. Significant reductions in operational expenses were noted, and participation in the upcoming TSC World Conference is planned.
Read more →FLNA▼ -5.6%on this news· ran to -17% by day 3
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
Filana Therapeutics has reported its Q1 2026 financial results, highlighting progress in its TSC-related epilepsy program. The company is addressing an FDA Clinical Hold and has published promising preclinical data on simufilam. Despite a net loss of $10.3 million, Filana maintains a solid cash position with no debt.
Read more →FLNAFilana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Filana Therapeutics announced the publication of preclinical data in 'Epilepsia' demonstrating that simufilam effectively attenuates seizure progression in a mouse model of Tuberous Sclerosis Complex (TSC). The study confirms previous findings and highlights the potential of simufilam as a treatment for TSC-related epilepsy, which affects around 45,000 individuals in the U.S. The company is addressing FDA inquiries related to a clinical hold.
Read more →FLNACassava Sciences Announces $ 50 Million Registered Direct Offering of Common Stock  AUSTIN, Texas, Nov. 18 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA ) (the “Company” or “Cassava
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Nov. 18, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it
Read more →FLNACassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign  AUSTIN, Texas – November 3 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA), a clinical-stage biot
Cassava Sciences Files Lawsuit Against Perpetrators of Short and Distort Campaign AUSTIN, Texas November 3, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individual
Read more →FLNACassava Sciences Announces Expansion of Leadership Team  · Chris Cook , A Skilled Litigator, To Join Management Team as General Counsel · New Position Is Expected to Be Critical to Operations and Strate
Cassava Sciences Announces Expansion of Leadership Team AUSTIN, Texas October 27, 2022 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced the expansion of its leadership team with the appointment of Christopher
Read more →FLNAxFEFF; Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer's Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Bri
Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer's Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Brignoni, Boris Nikolov, Hoau-Yan Wang, Zhe Pei, Antonio Hernandez, Ca
Read more →FLNAxFEFF;   Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease  - Selection of Premier Research as CRO Marks Significant Milestone Toward Init
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease - Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease - AUSTIN, Texas June 21, 2021
Read more →FLNAxFEFF; Cassava Sciences Announces the Appointment of  Richard J. Barry to its Board of Directors  - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals AUSTIN, Texas June 14, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA),
Read more →FLNAxFEFF;  Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam  AUSTIN, TX – March 9 , 2021 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam AUSTIN, TX March 9, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today announced it has entered into a drug suppl
Read more →FLNAxFEFF; Cassava Sciences Announces $ 200 Million Registered Direct Offering of Common Stock  AUSTIN, Texas, Feb . 10 , 20 21 – Cassava Sciences, Inc. (Nasdaq: SAVA ) (the “Company” or “
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock AUSTIN, Texas, Feb. 10, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that i
Read more →FLNAxFEFF; CASSAVA sciences We Focus on Alzheimer's disease February 2021 CASSAVA sciences 1  Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements, including statements made
CASSAVA sciences We Focus on Alzheimer's disease February 2021 CASSAVA sciences 1 Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Read more →FLNAxFEFF; Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer  Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company'
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease. AUSTIN, TX Jan
Read more →FLNAxFEFF; Cassava Sciences Announces Proposed Public Offering of Common Stock  AUSTIN, Texas, November 12 , 2020 – Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Science
Cassava Sciences Announces Proposed Public Offering of Common Stock AUSTIN, Texas, November 12, 2020 Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences ), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it is commen
Read more →FLNAxFEFF; Sumifilam Significantly Improves Eleven CSF Biomarkers in a Randomized, Placebo-controlled, One-month Clinical Trial in Alzheimer's Disease Patients Lindsay BURNS, Hoau-Yan WANG, Zhe PEI, Kuo-Chieh LEE, Yaneicy GO
Sumifilam Significantly Improves Eleven CSF Biomarkers in a Randomized, Placebo-controlled, One-month Clinical Trial in Alzheimer's Disease Patients Lindsay BURNS, Hoau-Yan WANG, Zhe PEI, Kuo-Chieh LEE, Yaneicy GONZALEZ-ROJAS, Tamara DOEHNER, John PUENTE, Patrick SCIARA, Brian BE
Read more →FLNAxFEFF; CASSAVA sciences Final Results of a Phase 2b Study of Sumifilam in Alzheimer's Disease
CASSAVA sciences Final Results of a Phase 2b Study of Sumifilam in Alzheimer's Disease September 14, 2020 1 Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Read more →FLNAxFEFF; CASSAVA SCIENCES One-month Oral Treatment with PTI-125, a New Drug Candidate, Reduces CSF & Plasma Biomarkers of Alzheimer's Disease Late Breaking Oral Communication 12th Clinical Trials on Alzheimer's Disease (CT
CASSAVA SCIENCES One-month Oral Treatment with PTI-125, a New Drug Candidate, Reduces CSF & Plasma Biomarkers of Alzheimer's Disease Late Breaking Oral Communication 12th Clinical Trials on Alzheimer's Disease (CTAD) December 5, 2019 - San Diego, CA Lindsay H. Burns, PhD; Hoau-Ya
Read more →FLNAPain Therapeutics, Inc.     Pain Therapeutics Announces Name Change to Cassava Sciences , Inc.   - Focus is on Neurodegenerative Diseases -  AUSTIN, TX – Mar
Pain Therapeutics, Inc. Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. - Focus is on Neurodegenerative Diseases - AUSTIN, TX March 27, 2019 Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced a company name change to Cassava Scienc
Read more →FLNAxFEFF;  Pain Therapeutics, Inc.   Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY  - Going Forward, We Will Be Silent Regarding Future Expectations for REMOXY -
Pain Therapeutics, Inc. Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY - Going Forward, We Will Be Silent Regarding Future Expectations for REMOXY - AUSTIN, TX February 5, 2019 Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug developm
Read more →FLNAxFEFF; Pain Therapeutics, Inc.  For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@pain trials.com (512) 501-2485  Pain Therapeutics Announces Appointment of Chief Financial Officer þ
Pain Therapeutics, Inc. For More Information Contact: Pain Therapeutics, Inc. Pain Therapeutics Announces Appointment of Chief Financial Officer AUSTIN, TX October 11, 2018 Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that Mr. Eric Sch
Read more →FLNAxFEFF;  Pain Therapeutics, Inc. Overview of Neuroprotection Program Non-confidential October 2018 NASDAQ: PTIE COPYRIGHT © Pain Therapeutics, Inc. 2018 1   Forward-Looking Statements This pre
Pain Therapeutics, Inc. Overview of Neuroprotection Program Non-confidential October 2018 NASDAQ: PTIE COPYRIGHT Pain Therapeutics, Inc. 2018 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigatio
Read more →FLNAxFEFF; Pain Therapeutics, Inc.   For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@paintrials.com (512) 501-2485   Pain Therapeutics Announces Closing of $11.3 Million Re
Pain Therapeutics, Inc. For More Information Contact: Pain Therapeutics, Inc. Pain Therapeutics Announces Closing of $11.3 Million Registered Direct Offering AUSTIN, Texas August 17, 2018 Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced the
Read more →FLNAxFEFF; Pain Therapeutics, Inc.  For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@pain trials.com (512) 501-2485   Pain Therapeutics Announces Reverse Stock Split - Stock to Trad
Pain Therapeutics, Inc. For More Information Contact: Pain Therapeutics, Inc. Pain Therapeutics Announces Reverse Stock Split - Stock to Trade on a Split-adjusted Basis Beginning May 10, 2017 - AUSTIN, Texas May 8, 2017 Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced
Read more →FLNAv073384_ex991.txt Pain Therapeutics Announces First Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today r
Pain Therapeutics Announces First Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the three months ended March 31, 2007. Net in
Read more →FLNAPAIN THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR-END 2006 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today repo
PAIN THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR-END 2006 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the year and fourth quarter en
Read more →FLNAPAIN THERAPEUTICS ANNOUNCES THIRD QUARTER 2006
PAIN THERAPEUTICS ANNOUNCES THIRD QUARTER 2006 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif. October 25, 2006 Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the three and nine months ended September 30, 2006. Net income
Read more →Competitive Position
How FLNA ranks across every disease it competes inCompetitive Position is a premium feature
See how FLNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial